The Food and Drug Administration (FDA) has granted breakthrough device designation to the Gazelle Hb Variant test, a point-of-care blood test developed by Hemex Health to enable rapid, low-cost diagnosis of sickle cell disease (SCD) and beta thalassemia. The designation is…